IQVIA Holdings Inc. $IQV is Keystone Investors PTE Ltd.’s 6th Largest Position

Keystone Investors PTE Ltd. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 68.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 245,924 shares of the medical research company’s stock after buying an additional 99,696 shares during the quarter. IQVIA comprises about 5.0% of Keystone Investors PTE Ltd.’s investment portfolio, making the stock its 6th largest holding. Keystone Investors PTE Ltd. owned approximately 0.14% of IQVIA worth $55,434,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $27,000. Gilpin Wealth Management LLC purchased a new position in shares of IQVIA in the 4th quarter valued at approximately $27,000. Measured Wealth Private Client Group LLC purchased a new position in shares of IQVIA in the 3rd quarter valued at approximately $30,000. Finally, Activest Wealth Management raised its position in shares of IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on IQV. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $174.00 to $213.00 in a research report on Monday, March 9th. HSBC set a $210.00 price objective on shares of IQVIA in a research report on Wednesday, June 3rd. Truist Financial decreased their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Royal Bank Of Canada began coverage on shares of IQVIA in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target for the company. Finally, Mizuho set a $215.00 price target on shares of IQVIA in a research report on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $224.13.

IQVIA Stock Performance

IQV opened at $181.10 on Friday. IQVIA Holdings Inc. has a 12-month low of $153.01 and a 12-month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market capitalization of $30.23 billion, a PE ratio of 22.44, a P/E/G ratio of 1.55 and a beta of 1.21. The firm has a 50 day moving average of $173.56 and a two-hundred day moving average of $193.68.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period last year, the firm posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s board of directors believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.